VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice

BACKGROUND: Chronic mucocutaneous candidiasis (CMC) treatment often induces drug resistance, posing long-term challenges. A novel broad-spectrum fungal CYP51 inhibitor, VT-1598, specifically targets fungal CYP51, but not human CYP enzymes. OBJECTIVES: To determine the efficacy of VT-1598 in the trea...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Antimicrob Chemother
Main Authors: Break, Timothy J, Desai, Jigar V, Healey, Kelley R, Natarajan, Mukil, Ferre, Elise M N, Henderson, Christina, Zelazny, Adrian, Siebenlist, Ulrich, Yates, Christopher M, Cohen, Oren J, Schotzinger, Robert J, Perlin, David S, Garvey, Edward P, Lionakis, Michail S
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6054247/
https://ncbi.nlm.nih.gov/pubmed/29788070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky170
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki